Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

by Masato Furuhashi, Shigeyuki Saitoh, Kazuaki Shimamoto, Tetsuji Miura
Published 2015-02-01

Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological Insights and Potent Clinical Biomarker of Metabolic and Cardiovascular Diseases

by Masato Furuhashi, Shigeyuki Saitoh, Kazuaki Shimamoto, Tetsuji Miura
Published 2014-01-01

Lipid Chaperones and Metabolic Inflammation

by Masato Furuhashi, Shutaro Ishimura, Hideki Ota, Tetsuji Miura
Published 2011-01-01

Correction: A Predominant Role for Parenchymal c-Jun Amino Terminal Kinase (JNK) in the Regulation of Systemic Insulin Sensitivity

by Sara N. Vallerie, Masato Furuhashi, Raquel Fucho, Gökhan S. Hotamisligil
Published 2009-01-01

A predominant role for parenchymal c-Jun amino terminal kinase (JNK) in the regulation of systemic insulin sensitivity.

by Sara N Vallerie, Masato Furuhashi, Raquel Fucho, Gökhan S Hotamisligil
Published 2008-09-01

Correction: A Predominant Role for Parenchymal c-Jun Amino Terminal Kinase (JNK) in the Regulation of Systemic Insulin Sensitivity.

by Sara N. Vallerie, Masato Furuhashi, Raquel Fucho, Gökhan S. Hotamisligil
Published 2009-01-01

Screening of the Drug-Induced Effects of Prostaglandin EP2 and FP Agonists on 3D Cultures of Dexamethasone-Treated Human Trabecular Meshwork Cells

by Megumi Watanabe, Yosuke Ida, Masato Furuhashi, Yuri Tsugeno, Hiroshi Ohguro, Fumihito Hikage
Published 2021-07-01

Detection of significantly high vitreous concentrations of fatty acid-binding protein 4 in patients with proliferative diabetic retinopathy

by Kaku Itoh, Masato Furuhashi, Yosuke Ida, Hiroshi Ohguro, Megumi Watanabe, Soma Suzuki, Fumihito Hikage
Published 2021-06-01

Fatty acid-binding protein 4 is an independent factor in the pathogenesis of retinal vein occlusion.

by Fumihito Hikage, Masato Furuhashi, Yosuke Ida, Hiroshi Ohguro, Megumi Watanabe, Soma Suzuki, Kaku Itoh
Published 2021-01-01

Possible Increase in Serum FABP4 Level Despite Adiposity Reduction by Canagliflozin, an SGLT2 Inhibitor.

by Masato Furuhashi, Megumi Matsumoto, Shinya Hiramitsu, Akina Omori, Marenao Tanaka, Norihito Moniwa, Hideaki Yoshida, Junnichi Ishii, Tetsuji Miura
Published 2016-01-01

Transcriptome and Metabolome Analyses in Exogenous FABP4- and FABP5-Treated Adipose-Derived Stem Cells.

by Tokunori Yamamoto, Masato Furuhashi, Takeshi Sugaya, Tsuyoshi Oikawa, Megumi Matsumoto, Yasuhito Funahashi, Yoshihisa Matsukawa, Momokazu Gotoh, Tetsuji Miura
Published 2016-01-01

Reply to the comment of Hirota et al. on “Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes”

by Tatsuya Sato, Hiroto Oshima, Kei Nakata, Yukishige Kimura, Toshiyuki Yano, Masato Furuhashi, Masaya Tannno, Takayuki Miki, Tetsuji Miura
Published 2020-01-01

Accuracy of flash glucose monitoring in insulin‐treated patients with type 2 diabetes

by Tatsuya Sato, Hiroto Oshima, Kei Nakata, Yukishige Kimura, Toshiyuki Yano, Masato Furuhashi, Masaya Tanno, Takayuki Miki, Tetsuji Miura
Published 2019-05-01

Serum fatty acid-binding protein 4 is a predictor of cardiovascular events in end-stage renal disease.

by Masato Furuhashi, Shutaro Ishimura, Hideki Ota, Manabu Hayashi, Takahiro Nishitani, Marenao Tanaka, Hideaki Yoshida, Kazuaki Shimamoto, Gökhan S Hotamisligil, Tetsuji Miura
Published 2011-01-01

A Case of Crescentic Glomerulonephritis Complicated with Hypocomplementemic Urticarial Vasculitis Syndrome and ANCA-Associated Vasculitis

by Marenao Tanaka, Norihito Moniwa, Tomohiro Mita, Toshiyuki Tobisawa, Tamaki Matsumoto, Atsushi Mochizuki, Tomohisa Yamashita, Toshiyuki Yano, Masato Furuhashi, Tetsuji Miura
Published 2017-11-01

Low urine pH predicts new onset of diabetes mellitus during a 10‐year period in men: BOREAS‐DM1 study

by Yukimura Higashiura, Marenao Tanaka, Masato Furuhashi, Masayuki Koyama, Hirofumi Ohnishi, Keita Numata, Takashi Hisasue, Nagisa Hanawa, Norihito Moniwa, Tetsuji Miura
Published 2020-11-01

Elevated circulating FABP4 concentration predicts cardiovascular death in a general population: a 12-year prospective study

by Norie Saito, Masato Furuhashi, Masayuki Koyama, Yukimura Higashiura, Hiroshi Akasaka, Marenao Tanaka, Norihito Moniwa, Hirofumi Ohnishi, Shigeyuki Saitoh, Nobuyuki Ura, Kazuaki Shimamoto, Tetsuji Miura
Published 2021-02-01

Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving st...

by Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
Published 2020-06-01

Independent and Distinct Associations of FABP4 and FABP5 With Metabolic Parameters in Type 2 Diabetes Mellitus

by Masato Furuhashi, Ichiro Sakuma, Takeshi Morimoto, Yukimura Higashiura, Akiko Sakai, Megumi Matsumoto, Mio Sakuma, Michio Shimabukuro, Takashi Nomiyama, Osamu Arasaki, Koichi Node, Shinichiro Ueda
Published 2020-09-01

Significance of urinary fatty acid-binding protein 4 level as a possible biomarker for the identification of minimal change disease in patents with nephrotic-range proteinuria

by Marenao Tanaka, Masato Furuhashi, Norihito Moniwa, Takuto Maeda, Hideki Takizawa, Megumi Matsumoto, Akiko Sakai, Yukimura Higashiura, Yufu Gocho, Masayuki Koyama, Yayoi Ogawa, Tetsuji Miura
Published 2020-11-01